Study of FXS887 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug, FXS887, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how it affects the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have an advanced solid tumor that has been confirmed by biopsy and has gotten worse after at least one previous treatment
- You have at least one tumor that can be measured on a scan
- You are able to take care of yourself (ECOG score 0 or 1) and expected to live at least 12 more weeks
- Your organs and bone marrow are working well enough, based on blood tests
- You are not pregnant, and if you could become pregnant, you agree to use effective birth control during the study and for 6 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage trial testing a new drug called FXB0871 to treat advanced cancers that have spread or haven't responded to standard treatments. The drug works by helping your immune system fight cancer cells.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
This trial tests a new drug called HS387 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how well it works.
This trial tests a new oral drug called SIGX1094R for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how well it works, and it requires a tumor tissue sample to look for a specific marker.
This trial tests a new drug (SIM0686) in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how it affects tumors that have a specific protein called FGFR2b on their surface.
Hear when a new Solid Tumor Refractory to Conventional Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.